% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Roser:186725,
      author       = {E. Roser and P. Harter and D. Zocholl and D. Denschlag and
                      R. Chekerov and P. Wimberger and C. Kurzeder and A.
                      Hasenburg and M.-Z. Muallem and A. Mustea and G. Emons and
                      A. G. Zeimet and F. Beck and T. Arndt and S. Y. Brucker and
                      S. Kommoss and F. Heitz and J. Welz and E.-K. Egger and M.
                      Kalder and P. Buderath and M. Klar and C. Marth and U. A.
                      Ulrich and M. Weigel and L. Traub and C. Anthuber and H.
                      Strauss and L. Hanker and T. Link and K. Kubiak and B.
                      Melekian and D. Hornung and M. Pölcher and B. Lampe and T.
                      Krauß and U. Keilholz$^*$ and A. Flörcken and K. Pietzner
                      and J. Sehouli},
      title        = {{T}reatment strategies in patients with gynecological
                      sarcoma: {R}esults of the prospective intergroup real-world
                      registry for gynecological sarcoma in {G}ermany
                      ({REGSA}-{NOGGO} {RU}1).},
      journal      = {International journal of gynecological cancer},
      volume       = {33},
      number       = {2},
      issn         = {1048-891X},
      address      = {London},
      publisher    = {BMJ Publishing Group Ltd},
      reportid     = {DKFZ-2023-00077},
      pages        = {223-230},
      year         = {2023},
      note         = {2023 Feb 6;33(2):223-230},
      abstract     = {Gynecological sarcomas account for $3\%$ of all
                      gynecological malignancies and are associated with a poor
                      prognosis. Due to the rarity and heterogeneity of
                      gynecological sarcomas there is still no consensus on
                      optimal therapeutic strategies. This study's objective was
                      to describe the treatment strategies used in patients with
                      gynecological sarcomas in the primary course of disease.The
                      German prospective registry for gynecological sarcoma
                      (REGSA) is the largest registry for gynecological sarcomas
                      in Germany, Austria and Switzerland. Primary inclusion
                      criteria for REGSA are histological diagnosis of sarcoma of
                      the female genital tract, sarcoma of the breast or uterine
                      smooth muscle tumors of uncertain malignant potential
                      (STUMP). We evaluated data of the REGSA registry on
                      therapeutic strategies used for primary treatment from
                      August 2015 to February 2021.A total of 723 patients from
                      120 centers were included. Data on therapeutic strategies
                      for primary treatment were available in 605 cases. Overall,
                      580 $(95.9\%)$ patients underwent primary surgery, 472
                      $(81.4\%)$ of whom underwent only hysterectomy. Morcellation
                      was reported in $11.4\%$ (n=54) of all hysterectomies. A
                      total of $42.8\%$ (n=202) had no further surgical
                      interventions, whereas an additional salpingo-ophorectomy
                      was performed in $54\%$ (n=255) of patients. An additional
                      lymphadenectomy was performed in $12.7\%$ (n=60), an
                      omentectomy in $9.5\%$ (n=45) and intestinal resection in
                      $6.1\%$ (n=29) of all patients. Among 448 patients with
                      available information, $21.4\%$ (n=96) received chemo- or
                      targeted therapies, more commonly as single-agent treatment
                      than as drug combinations. Information about anti-hormonal
                      treatment was available for 423 patients, among which 42
                      $(9.9\%)$ received anti-hormonal treatment, 23 $(54.8\%)$ of
                      whom with low-grade endometrial stroma sarcomas. For
                      radiotherapy, data of 437 patients were available, among
                      which 29 $(6.6\%)$ patients underwent radiotherapy.Our study
                      showed that treatment of patients with gynecologic sarcomas
                      is heterogeneous. Further trials are needed along with more
                      information on treatment modalities, therapy response and
                      patient-reported outcomes to implement new treatment
                      strategies.},
      keywords     = {gynecologic surgical procedures (Other) / gynecology
                      (Other) / sarcoma (Other)},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36631151},
      doi          = {10.1136/ijgc-2022-003800},
      url          = {https://inrepo02.dkfz.de/record/186725},
}